Ascendis Pharma A (ASND) Research & Development (2014 - 2026)

Ascendis Pharma A has disclosed Research & Development across 13 years of filings, most recently posting -$69.1 million for Q1 2026.

• Research & Development for Q1 2026 came in at -$69.1 million, up 24.12% year-over-year; the trailing twelve-month figure through Mar 2026 was -$156.8 million (up 5.94% YoY), and the FY2025 annual result was $353.4 million, up 7.73% from the prior year.
• Research & Development came in at -$69.1 million for Q1 2026 at Ascendis Pharma A, up from -$91.0 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $121.3 million in Q3 2023 to a low of -$91.1 million in Q1 2025.
• The 5-year median for Research & Development is $89.9 million (2024), against an average of $35.3 million.
• Across the five-year window, Research & Development surged 47.55% in 2022 and sank 218.63% in 2025, its largest moves.
• Ascendis Pharma A's Research & Development stood at $110.8 million in 2022, then slipped by 11.76% to $97.8 million in 2023, then sank by 186.65% to -$84.7 million in 2024, then retreated by 7.36% to -$91.0 million in 2025, then grew by 24.01% to -$69.1 million in 2026.
• The last three Research & Development figures came in at -$69.1 million (Q1 2026), -$91.0 million (Q4 2025), and -$78.2 million (Q3 2025), per Business Quant data.